Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Blood Specimen Collection 4Liquid Biopsy 2trastuzumab deruxtecan 1tislelizumab 1fludarabine phosphate 1fludarabine 1Pirinitramide 1Oxaliplatin 1Neoadjuvant Therapy 1Morphine 1Leucovorin 1Irinotecan 1HMPL-013 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Cetuximab 1Analgesia, Epidural 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × AP 1903 reagent × Gastrointestinal × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡